Document Type : Original Article
Authors
1 Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran
2 Child Growth and Developmental Research Center, Research Institute for Primordial Prevention of Noncommunicable Diseases, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Objective: Epilepsy is a chronic neurological disorder that affects 0.5%–1%
of children. 30%–40% of patients are resistant to current anti-epileptic drugs.
Lacosamide (LCM) appeared to be effective, safe, and well tolerated in children
and adolescents. This study was aimed to evaluate whether LCM could be an
effective add-on therapy in children with refractory focal epilepsies. Methods: This
study was conducted from April 2020 to April 2021 in Imam Hossein Children
Hospital, Isfahan, Iran. We included 44 children aged 6 months to 16 years with
refractory focal epilepsy (based on International League Against Epilepsy criteria).
LCM was given in divided doses of 2 mg/kg/day, increasing by 2 mg/kg every
week. The first follow‑up visit was 6 weeks later, when all patients had reached
the therapeutic dose. Findings: The average age of the patients was 89.9 months.
72.5% of children had focal motor seizures. Evaluation of percent change in seizure
frequency and duration before and after treatment showed a 53.22% reduction in
seizure frequency and 43.72% reduction in seizure duration after treatment. Our
study group tolerated LCM well, with few side effects. Headache, dizziness, and
nausea were common side effects. In line with other studies, none of the suspected
risk factors could predict response to LCM treatment. Conclusion: LCM appears
to be an effective, safe, and well-tolerated medication in children with uncontrolled
drug-resistant focal epilepsy.
Keywords
- Berg AT, Rychlik K. The course of childhood-onset epilepsy over
the first two decades: A prospective, longitudinal study. Epilepsia
2015;56:40-8.
2. Bemanalizadeh M, Yazdi M, Yaghini O, Kelishadi R. A metaanalysis on the effect of telemedicine on the management
of attention deficit and hyperactivity disorder in children
and adolescents. Journal of Telemedicine and Telecare 2021.
doi:10.1177/1357633X211045186.
3. Dudley RW, Penney SJ, Buckley DJ. First-drug treatment
failures in children newly diagnosed with epilepsy. Pediatr
Neurol 2009;40:71-7.
4. Ahadi P, Nasiri J, Ghazavi MR, Mosavian T, Mansouri V.
A comparative study on the efficacy of levetiracetam and
carbamazepine in the treatment of rolandic seizures in children:
An open-label randomized controlled trial. J Res Pharm Pract
2020;9:68-72.
5. Geerts A, Arts WF, Stroink H, Peeters E, Brouwer O, Peters B,
et al. Course and outcome of childhood epilepsy: A 15-year
follow-up of the Dutch study of epilepsy in childhood. Epilepsia
2010;51:1189-97.
6. Cawello W. Clinical pharmacokinetic and pharmacodynamic
profile of lacosamide. Clin Pharmacokinet 2015;54:901‑14.
7. Doty P, Hebert D, Mathy FX, Byrnes W, Zackheim J,
Simontacchi K. Development of lacosamide for the treatment of
partial‑onset seizures. Ann N Y Acad Sci 2013;1291:56‑68.
8. Niespodziany I, Leclère N, Vandenplas C, Foerch P, Wolff C.
Comparative study of lacosamide and classical sodium channel
blocking antiepileptic drugs on sodium channel slow inactivation.
J Neurosci Res 2013;91:436-43.
9. Verrotti A, Loiacono G, Olivieri C, Zulli E, Zaccara G.
Lacosamide in patients with pharmacoresistant epilepsy. Expert
Opin Pharmacother 2012;13:2065-72.
10. Brodie MJ. Practical use of newer antiepileptic drugs
as adjunctive therapy in focal epilepsy. CNS Drugs
2015;29:893-904.
11. Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB.
Safety and tolerability of lacosamide as adjunctive therapy for
adults with partial-onset seizures: Analysis of data pooled from
three randomized, double-blind, placebo-controlled clinical trials.
Epilepsy Behav 2015;52:119-27.
12. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W,
Mathern G, et al. Definition of drug resistant epilepsy: Consensus
proposal by the ad hoc task force of the ILAE commission on
therapeutic strategies. Epilepsia 2010;51:1069-77.
13. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J,
Guilhoto L, et al. ILAE classification of the epilepsies: Position
paper of the ILAE commission for classification and terminology.
Epilepsia 2017;58:512-21.
14. Farkas V, Steinborn B, Flamini JR, Zhang Y, Yuen N,
Borghs S, et al. Efficacy and tolerability of adjunctive
lacosamide in pediatric patients with focal seizures. Neurology
2019;93:e1212-26.
15. Rosati A, Ilvento L, Rizzi R, Doccini V, Leo MC, Pugi A, et al.
Long‑term efficacy of add‑on lacosamide treatment in children
and adolescents with refractory epilepsies: A single-center
observational study. Epilepsia 2018;59:1004-10.
16. Kim JS, Kim H, Lim BC, Chae JH, Choi J, Kim KJ, et al.
Lacosamide as an adjunctive therapy in pediatric patients with
refractory focal epilepsy. Brain Dev 2014;36:510-5.
17. Guilhoto LM, Loddenkemper T, Gooty VD, Rotenberg A,
Takeoka M, Duffy FH, et al. Experience with lacosamide in a
series of children with drug-resistant focal epilepsy. Pediatr
Neurol 2011;44:414-9.
18. Pasha I, Kamate M, Didagi SK. Efficacy and tolerability of
lacosamide as an adjunctive therapy in children with refractory
partial epilepsy. Pediatr Neurol 2014;51:509-14.
19. Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P. Efficacy
and safety of lacosamide in infants and young children with
refractory focal epilepsy. Eur J Paediatr Neurol 2014;18:55-9.
20. Yıldırım C, Coşkun Y. The efficacy of lacosamide in children
with drug‑resistant focal epilepsy. Med J Haydarpaşa Numune
Train Res Hosp 2021;61:52-7.
21. Ortiz de la Rosa JS, Ladino LD, Rodríguez PJ, Rueda MC,
Polanía JP, Castañeda AC. Efficacy of lacosamide in children
and adolescents with drug-resistant epilepsy and refractory status
epilepticus: A systematic review. Seizure 2018;56:34-40. - 22. Arkilo D, Gustafson M, Ritter FJ. Clinical experience of
intravenous lacosamide in infants and young children. Eur J
Paediatr Neurol 2016;20:212-7.
23. Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R.
Preliminary efficacy and safety of lacosamide in children with
refractory epilepsy. Eur J Paediatr Neurol 2012;16:15-9.
24. Toupin JF, Lortie A, Major P, Diadori P, Vanasse M, Rossignol E,
et al. Efficacy and safety of lacosamide as an adjunctive therapy
for refractory focal epilepsy in paediatric patients: A retrospective
single-centre study. Epileptic Disord 2015;17:436-43.
25. Yildiz EP, Ozkan MU, Bektas G, Uzunhan TA, Aydinli N,
Caliskan M, et al. Lacosamide treatment of childhood refractory
focal epilepsy: The first reported side effect in paediatric patients.
Childs Nerv Syst 2017;33:2023-7.
26. Sawh SC, Newman JJ, Deshpande S, Jones PM. Lacosamide
adjunctive therapy for partial-onset seizures: A meta-analysis.
PeerJ 2013;1:e114.
27. Zangaladze A, Skidmore C. Lacosamide use in refractory
idiopathic primary generalized epilepsy. Epilepsy Behav
2012;23:79-80.
)